Biotech Losers: China Biologic Products (NASDAQ:CBPO), Heat Biologics (NASDAQ:HTBX), Recro Pharma Inc (NASDAQ:REPH), Egalet Corp (NASDAQ:EGLT)

China Biologic Products, Inc. (NASDAQ:CBPO), a leading fully integrated plasma-based biopharmaceutical company in China , today announced its financial results for the fourth quarter and fiscal year 2013. China Biologic Products Inc (NASDAQ:CBPO) stock performance was -6.25% in last session and finished the day at $32.85. Traded volume was 32,311.00million shares in the last session and the average volume of the stock remained 21.68K shares. The beta of the stock remained 1.84. China Biologic Products Inc (NASDAQ:CBPO) insider ownership is 72.36%.

Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a corporate overview at the MaidStone Life Sciences LLC 4th Annual”Cancer Immunotherapy: A Long-Awaited Reality”conference on March 27, 2014 at 10:30 a.m. Eastern Time at the New York Academy of Medicine in New York City. Heat Biologics Inc (NASDAQ:HTBX) dropped -9.78 percent to $6.64 Thursday on volume of 46,289.00million shares. The intra-day range of the stock was $6.50 to $7.33. Heat Biologics Inc (NASDAQ:HTBX) has a market capitalization of $42.27million.

In connection with the initial public offering (the “IPO”) of shares of common stock of Recro Pharma, Inc. (NASDAQ:REPH), the election of Alfred Altomari and Michael Berelowitz as members of the board of directors of the Company became effective, as contemplated by the Company’s prospectus, dated March 6, 2014 (the “Prospectus”), filed with the Securities and Exchange Commission pursuant to Rule 424(b) promulgated under the Securities Act of 1933, as amended, which is deemed part of the Company’s Registration Statement on Form S-1, as amended (File No. 333-191879) (the “Registration Statement”). Recro Pharma Inc (NASDAQ:REPH)’s stock on Mar 27, 2014 reported a decrease of -8.22% to the closing price of $7.15. Its fifty two weeks range is $7.01 -$9.88. The total market capitalization recorded $51.09million. The overall volume in the last trading session was 95,756.00million shares. In its share capital, REPH has 5.38million outstanding shares.

Egalet Corporation (NASDAQ:EGLT) today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet Corporation (NASDAQ:EGLT) is reporting its operating results as a public company. On Thursday, shares of Egalet Corporation (NASDAQ:EGLT) dropped -9.40% to close the day at $13.01. Company return on investment (ROI) is 46.90% and its monthly performance is recorded as 2.44%.